Cooper Companies (NASDAQ:COO) Releases FY 2026 Earnings Guidance

Posted by George Bondi on Sep 10th, 2026

Cooper Companies (NASDAQ:COO – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.510-4.550 for the period, compared to the consensus EPS estimate of 4.630. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.3 billion. Cooper Companies also updated its Q4 2026 guidance to 1.050-1.090 EPS.

Cooper Companies Stock Down 6.2%

Shares of Cooper Companies stock opened at $63.48 on Thursday. The company has a market cap of $12.38 billion, a P/E ratio of 53.80, a PEG ratio of 1.77 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. Cooper Companies has a one year low of $58.89 and a one year high of $89.83. The firm has a fifty day moving average of $72.42 and a two-hundred day moving average of $70.02.

Cooper Companies (NASDAQ:COO – Get Free Report) last issued its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, analysts forecast that Cooper Companies will post 4.63 earnings per share for the current year.

Cooper Companies declared that its Board of Directors has initiated a share repurchase program on Wednesday, September 9th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

A number of analysts recently weighed in on COO shares. Stifel Nicolaus decreased their price target on Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. JPMorgan Chase & Co. reduced their target price on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a report on Friday, June 5th. Weiss Ratings restated a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. The Goldman Sachs Group set a $61.00 price target on shares of Cooper Companies in a report on Wednesday, May 27th. Finally, Wells Fargo & Company restated a “sell” rating and issued a $66.00 price target (down from $82.00) on shares of Cooper Companies in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $78.00.

View Our Latest Stock Analysis on COO

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

Positive Sentiment: CooperCompanies reported fiscal third-quarter adjusted EPS of $1.15, ahead of the $1.11–$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
Positive Sentiment: The board expanded its share-repurchase authorization from $2 billion to $3 billion, potentially allowing the company to buy back as much as 22.7% of outstanding shares. Management also repurchased $339.1 million of stock during the quarter, supporting per-share value if executed effectively. CooperCompanies Completes Strategic Review
Neutral Sentiment: GAAP EPS was $2.24, helped substantially by a $307.2 million discrete tax benefit related to the favorable completion of a U.K. tax examination. This benefit improves reported results but is not representative of recurring operating performance. CooperCompanies Reports Third-Quarter Results
Negative Sentiment: CooperCompanies lowered fiscal 2026 adjusted EPS guidance to $4.51–$4.55, below the roughly $4.63 consensus, and set fourth-quarter EPS guidance at $1.05–$1.09 versus expectations near $1.20. Full-year revenue guidance of $4.229–$4.252 billion also implies modest growth.
Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because potential offers were not sufficiently attractive. Investors appear disappointed that the company did not unlock value through a sale, particularly amid fertility-related litigation costs and competitive pressure in the IUD market. Reasons Cooper Companies Stock Is Under Pressure

Institutional Investors Weigh In On Cooper Companies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in Cooper Companies by 2.4% in the 4th quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock worth $720,736,000 after buying an additional 207,195 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after acquiring an additional 4,756,178 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Cooper Companies by 58.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock worth $494,123,000 after acquiring an additional 2,231,568 shares during the last quarter. Sustainable Growth Advisers LP increased its position in shares of Cooper Companies by 22.1% during the third quarter. Sustainable Growth Advisers LP now owns 4,132,535 shares of the medical device company’s stock worth $283,327,000 after acquiring an additional 747,476 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of Cooper Companies by 98.8% in the second quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock worth $241,120,000 after acquiring an additional 1,683,561 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

About Cooper Companies

(Get Free Report)

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.